Adult Dosing
Congestive Heart Failure
- Loading dose: 0.75 mg/kg IV over 2-3 min. If required, additional loading dose of 0.75 mg/kg IV may be given 30 minutes after the initiation of therapy
- Maintenance dose: 5 mcg/kg/min - 10 mcg/kg/min
- Max dose: 10 mg/kg/day
Notes: - Loading doses should be administered without dilution
- Infusion to be diluted in 0.9% or 0.45% saline to a concentration of 1-3 mg/mL
- Do not dilute with dextrose-containing solutions prior to injection. However, inamrinone may be injected into running dextrose infusions through a Y-Connector or directly into the tubing. Do not infuse inamrinone and furosemide through the same IV line
- Use diluted solutions within 24 hrs
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
Advanced Cardiovascular Life Support [Not FDA Approved]
- Loading dose 0.75-1 mg/kg IV or intraosseous over 5 minutes x1-3 doses, followed by an infusion of 2-20 mcg/kg/min
- The preparation contains sodium metabisulfite, which may cause anaphylactic reactions and life-threatening or less severe asthmatic episodes in susceptible people. Sulfite sensitivity is more frequent in asthmatic than in nonasthmatic people
- Avoid use in patients with severe aortic or pulmonic valvular disease and in acute phase of MI. It may aggravate outflow tract obstruction in hypertrophic subaortic stenosis
- Monitor blood pressure and heart rate during therapy; rate of infusion should be slowed or stopped in patients with significant decrease in BP
- Vigorous diuretic therapy may cause insufficient cardiac filling pressure leading to inadequate response to inamrinone therapy; fluids and electrolyte intake may be needed
- Monitoring central venous pressure (CVP) may be necessary in the assessment of hypotension and fluid balance management
- Supraventricular and ventricular arrhythmias may occur during therapy in the very high-risk population
- Monitor fluid and electrolyte changes, and renal function during inamrinone therapy. Potassium loss due to excessive diuresis may predispose digitalized patients to arrhythmias. Hypokalemia is to be corrected prior to or during treatment
- Thrombocytopenia and hepatotoxicity have been observed, more commonly in those receiving prolonged therapy. Monitor platelet counts and liver enzyme levels
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
Pregnancy Category:C
Breastfeeding: Safety unknown. As per manufacturer's data, caution should be exercised when administered to nursing women because it is not known whether the drug is excreted in breast milk.
US Trade Name(s)
US Availability
inamrinone (generic) [Discontinued]
- INJ: 5 mg/mL (20 mL vial)
Canadian Trade Name(s)
Canadian Availability
UK Trade Name(s)
UK Availability
Australian Trade Name(s)
Australian Availability